• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma.

作者信息

Rocchi Serena, Tacchetti Paola, Pantani Lucia, Mancuso Katia, Zannetti Beatrice, Cavo Michele, Zamagni Elena

机构信息

"Seràgnoli" Institute of Hematology, Bologna University School of Medicine, Italy.

"Seràgnoli" Institute of Hematology, Bologna University School of Medicine, Italy

出版信息

Haematologica. 2018 Jun;103(6):e277-e278. doi: 10.3324/haematol.2018.191122. Epub 2018 Apr 5.

DOI:10.3324/haematol.2018.191122
PMID:29622654
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6058770/
Abstract
摘要

相似文献

1
Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma.达雷妥尤单抗在多发性骨髓瘤继发的透析依赖型肾衰竭中的安全性和有效性。
Haematologica. 2018 Jun;103(6):e277-e278. doi: 10.3324/haematol.2018.191122. Epub 2018 Apr 5.
2
Safety and efficacy of daratumumab in patients with multiple myeloma and severe renal failure.达雷妥尤单抗在多发性骨髓瘤合并严重肾衰竭患者中的安全性和有效性。
Br J Haematol. 2021 May;193(4):e33-e36. doi: 10.1111/bjh.17412. Epub 2021 Mar 21.
3
Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis.达雷妥尤单抗耐药在晚期多发性骨髓瘤患者中很常见，与 CD38 表达无关，与预后不良有关。
Eur J Haematol. 2018 May;100(5):494-501. doi: 10.1111/ejh.13046. Epub 2018 Mar 25.
4
Daratumumab for the Treatment of Multiple Myeloma.达雷妥尤单抗治疗多发性骨髓瘤。
Front Immunol. 2018 Jun 4;9:1228. doi: 10.3389/fimmu.2018.01228. eCollection 2018.
5
Daratumumab Monotherapy in Heavily Pretreated Asian Patients With Relapsed and Refractory Multiple Myeloma: A Real-world Experience.达雷妥尤单抗单药治疗复发/难治性多发性骨髓瘤的亚洲广泛预处理患者：真实世界经验。
Anticancer Res. 2019 Sep;39(9):5165-5170. doi: 10.21873/anticanres.13712.
6
The impact of the introduction of bortezomib on dialysis independence in multiple myeloma patients with renal impairment: a nationwide Dutch population-based study.硼替佐米的引入对肾功能损害的多发性骨髓瘤患者透析独立性的影响：一项基于荷兰全国人口的研究。
Haematologica. 2018 Jul;103(7):e311-e314. doi: 10.3324/haematol.2017.184754. Epub 2018 Mar 15.
7
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.达雷妥尤单抗单药治疗治疗难治性多发性骨髓瘤患者（SIRIUS）：一项开放标签、随机、2 期试验。
Lancet. 2016 Apr 9;387(10027):1551-1560. doi: 10.1016/S0140-6736(15)01120-4. Epub 2016 Jan 7.
8
Daratumumab proves safe and highly effective in AL amyloidosis.达雷妥尤单抗在AL淀粉样变性中被证明是安全且高效的。
Br J Haematol. 2019 Apr;185(2):342-344. doi: 10.1111/bjh.15455. Epub 2018 Jun 25.
9
[Dialysis-dependent renal failure in patients with multiple myeloma: Reversibility factors].
Ter Arkh. 2015;87(7):72-76. doi: 10.17116/terarkh201587772-76.
10
Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma.达雷妥尤单抗治疗复发/难治性多发性骨髓瘤患者剂量方案的复杂药代动力学的临床意义
Clin Pharmacol Ther. 2017 Jun;101(6):721-724. doi: 10.1002/cpt.577. Epub 2017 Feb 13.

引用本文的文献

1
Dialysis dependence is associated with poor prognosis in multiple myeloma: a multicenter retrospective cohort study.透析依赖与多发性骨髓瘤的不良预后相关：一项多中心回顾性队列研究。
Ther Adv Med Oncol. 2025 Aug 21;17:17588359251357682. doi: 10.1177/17588359251357682. eCollection 2025.
2
Early daratumumab therapy improves renal outcomes in newly diagnosed patients with myeloma admitted with kidney injury.早期达雷妥尤单抗治疗可改善新诊断的合并肾损伤入院的骨髓瘤患者的肾脏预后。
Blood Adv. 2025 Jul 8;9(13):3129-3135. doi: 10.1182/bloodadvances.2025015901.
3
Evaluation of anti-CD38 monoclonal antibody-based immunotherapy in multiple myeloma with renal insufficiency: a systematic review and meta-analysis.基于抗CD38单克隆抗体的免疫疗法在伴有肾功能不全的多发性骨髓瘤中的评估：一项系统评价和荟萃分析。
Ther Adv Hematol. 2025 Feb 17;16:20406207251319593. doi: 10.1177/20406207251319593. eCollection 2025.
4
Recent Updates in the Diagnosis and Management of Kidney Diseases in Multiple Myeloma.多发性骨髓瘤肾脏疾病诊断与管理的最新进展
Indian J Nephrol. 2025 Jan-Feb;35(1):8-20. doi: 10.25259/ijn_491_23. Epub 2024 Jul 24.
5
The Role of Monoclonal Antibodies in the Treatment of Myeloma Kidney Disease.单克隆抗体在骨髓瘤肾病治疗中的作用
Pharmaceuticals (Basel). 2024 Aug 5;17(8):1029. doi: 10.3390/ph17081029.
6
High-cutoff hemodialysis in multiple myeloma patients with acute kidney injury.急性肾损伤的多发性骨髓瘤患者的高通量血液透析
Front Oncol. 2022 Oct 26;12:1024133. doi: 10.3389/fonc.2022.1024133. eCollection 2022.
7
An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment.复发/难治性多发性骨髓瘤合并肾功能损害患者的治疗选择概述
Ther Adv Hematol. 2022 Apr 2;13:20406207221088458. doi: 10.1177/20406207221088458. eCollection 2022.
8
Practical Considerations for the Daratumumab Management in Portuguese Routine Clinical Practice: Recommendations From an Expert Panel of Hematologists.葡萄牙常规临床实践中达雷妥尤单抗管理的实际考量：血液科专家小组的建议
Front Oncol. 2022 Feb 4;11:817762. doi: 10.3389/fonc.2021.817762. eCollection 2021.
9
Speckle Noise Algorithm-Based Ultrasound Imaging in Evaluating the Therapeutic Effect of Blood Purification on Children with Kidney Failure and Analysis of Its Correlation with Serum Inflammatory Factor Levels.基于散斑噪声算法的超声成像评价血液净化对肾衰竭患儿的治疗效果及与血清炎症因子水平的相关性分析。
J Healthc Eng. 2022 Jan 29;2022:3384102. doi: 10.1155/2022/3384102. eCollection 2022.
10
Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis.达雷妥尤单抗联合CyBorD方案用于新诊断的轻链型（AL）淀粉样变性患者。
Ther Adv Hematol. 2021 Nov 23;12:20406207211058334. doi: 10.1177/20406207211058334. eCollection 2021.

本文引用的文献

1
Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial.泊马度胺联合低剂量地塞米松治疗复发/难治性多发性骨髓瘤伴肾功能损害患者的疗效：一项 II 期试验结果。
J Clin Oncol. 2018 Jul 10;36(20):2035-2043. doi: 10.1200/JCO.2017.76.1742. Epub 2018 Feb 2.
2
Case Report: Treatment of light-chain amyloidosis with daratumumab monotherapy in two patients.病例报告：两例患者采用达雷妥尤单抗单药治疗轻链淀粉样变性。
Eur J Haematol. 2018 Apr;100(4):386-388. doi: 10.1111/ejh.13008. Epub 2018 Jan 1.
3
Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials.在临床试验之外接受基于达雷妥尤单抗的治疗的复发/难治性多发性骨髓瘤患者的疗效。
Am J Hematol. 2017 Nov;92(11):1146-1155. doi: 10.1002/ajh.24883. Epub 2017 Sep 8.
4
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.达雷妥尤单抗联合泊马度胺及地塞米松治疗复发和/或难治性多发性骨髓瘤
Blood. 2017 Aug 24;130(8):974-981. doi: 10.1182/blood-2017-05-785246. Epub 2017 Jun 21.
5
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.达雷妥尤单抗、来那度胺和地塞米松治疗多发性骨髓瘤。
N Engl J Med. 2016 Oct 6;375(14):1319-1331. doi: 10.1056/NEJMoa1607751.
6
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.达雷妥尤单抗、硼替佐米和地塞米松治疗多发性骨髓瘤。
N Engl J Med. 2016 Aug 25;375(8):754-66. doi: 10.1056/NEJMoa1606038.
7
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.国际骨髓瘤工作组多发性骨髓瘤反应和微小残留病评估的共识标准。
Lancet Oncol. 2016 Aug;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6.
8
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.达雷妥尤单抗可清除CD38+免疫调节细胞，促进T细胞扩增，并使多发性骨髓瘤中的T细胞库发生偏移。
Blood. 2016 Jul 21;128(3):384-94. doi: 10.1182/blood-2015-12-687749. Epub 2016 May 24.
9
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.达雷妥尤单抗单药治疗在多次预处理的复发或难治性多发性骨髓瘤患者中的临床疗效。
Blood. 2016 Jul 7;128(1):37-44. doi: 10.1182/blood-2016-03-705210. Epub 2016 May 23.
10
Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.达雷妥尤单抗，一种新型 CD38 单克隆抗体，在骨髓瘤中的应用的实际考虑。
Drugs. 2016 May;76(8):853-67. doi: 10.1007/s40265-016-0573-4.